HIV neutralizing antibodies: clinical correlates and implications for vaccines.
作者信息
Doria-Rose Nicole A
出版信息
J Infect Dis. 2010 Apr 1;201(7):981-3. doi: 10.1086/651143.
Abstract
摘要
相似文献
1
HIV neutralizing antibodies: clinical correlates and implications for vaccines.
J Infect Dis. 2010 Apr 1;201(7):981-3. doi: 10.1086/651143.
2
HIV Vaccines: One Step Closer.
Trends Mol Med. 2017 Jan;23(1):1-3. doi: 10.1016/j.molmed.2016.10.006. Epub 2016 Nov 23.
3
Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning.
Nat Rev Immunol. 2013 Sep;13(9):693-701. doi: 10.1038/nri3516.
4
HIV vaccine development--improving on natural immunity.
N Engl J Med. 2011 Sep 8;365(10):873-5. doi: 10.1056/NEJMp1107621.
5
Tiny steps towards an HIV vaccine.
Nature. 2010 Jul 15;466(7304):S8. doi: 10.1038/nature09238.
6
Recent strategies targeting HIV glycans in vaccine design.
Nat Chem Biol. 2014 Dec;10(12):990-9. doi: 10.1038/nchembio.1685.
7
Cure of HIV infection: is the long wait over?
J Allergy Clin Immunol. 2014 Jul;134(1):20-2. doi: 10.1016/j.jaci.2014.04.013. Epub 2014 Jun 26.
8
Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention.
Annu Rev Immunol. 2020 Apr 26;38:673-703. doi: 10.1146/annurev-immunol-080219-023629.
9
Lessons learned from HIV-1 vaccine trials: new priorities and directions.
Nat Immunol. 2012 Apr 18;13(5):423-7. doi: 10.1038/ni.2264.
10
The potential of broadly neutralizing antibodies for HIV prevention.
J Int AIDS Soc. 2024 May;27(5):e26257. doi: 10.1002/jia2.26257.
引用本文的文献
1
Three families of CD4-induced antibodies are associated with the capacity of plasma from people living with HIV to mediate ADCC in the presence of CD4-mimetics.
J Virol. 2024 Oct 22;98(10):e0096024. doi: 10.1128/jvi.00960-24. Epub 2024 Sep 4.
2
Functional development of a V3/glycan-specific broadly neutralizing antibody isolated from a case of HIV superinfection.
Elife. 2021 Jul 15;10:e68110. doi: 10.7554/eLife.68110.
3
SARS-CoV-2 Portrayed against HIV: Contrary Viral Strategies in Similar Disguise.
Microorganisms. 2021 Jun 27;9(7):1389. doi: 10.3390/microorganisms9071389.
4
Plasma IL-5 but Not CXCL13 Correlates With Neutralization Breadth in HIV-Infected Children.
Front Immunol. 2019 Jul 2;10:1497. doi: 10.3389/fimmu.2019.01497. eCollection 2019.
5
The Antibodiome-Mapping the Humoral Immune Response to HIV.
Curr HIV/AIDS Rep. 2019 Apr;16(2):169-179. doi: 10.1007/s11904-019-00432-x.
6
High-Frequency, Functional HIV-Specific T-Follicular Helper and Regulatory Cells Are Present Within Germinal Centers in Children but Not Adults.
Front Immunol. 2018 Sep 12;9:1975. doi: 10.3389/fimmu.2018.01975. eCollection 2018.
7
Activation-induced Markers Detect Vaccine-Specific CD4⁺ T Cell Responses Not Measured by Assays Conventionally Used in Clinical Trials.
Vaccines (Basel). 2018 Jul 31;6(3):50. doi: 10.3390/vaccines6030050.
8
An Outdated Notion of Antibody Specificity is One of the Major Detrimental Assumptions of the Structure-Based Reverse Vaccinology Paradigm, Which Prevented It from Helping to Develop an Effective HIV-1 Vaccine.
Front Immunol. 2014 Nov 18;5:593. doi: 10.3389/fimmu.2014.00593. eCollection 2014.
9
Neutralizing antibodies and control of HIV: moves and countermoves.
Curr HIV/AIDS Rep. 2012 Mar;9(1):64-72. doi: 10.1007/s11904-011-0105-5.
本文引用的文献
1
Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression.
J Infect Dis. 2010 Apr 1;201(7):1045-53. doi: 10.1086/651144.
2
Distribution, persistence, and efficacy of adoptively transferred central and effector memory-derived autologous simian immunodeficiency virus-specific CD8+ T cell clones in rhesus macaques during acute infection.
J Immunol. 2010 Jan 1;184(1):315-26. doi: 10.4049/jimmunol.0902410. Epub 2009 Nov 30.
3
Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables.
J Virol. 2010 Feb;84(3):1631-6. doi: 10.1128/JVI.01482-09. Epub 2009 Nov 18.
4
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.
N Engl J Med. 2009 Dec 3;361(23):2209-20. doi: 10.1056/NEJMoa0908492. Epub 2009 Oct 20.
5
Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression.
J Virol. 2009 Oct;83(19):10269-74. doi: 10.1128/JVI.01149-09. Epub 2009 Jul 29.
6
Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors.
J Virol. 2009 Sep;83(17):8925-37. doi: 10.1128/JVI.00758-09. Epub 2009 Jun 24.
7
Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques.
Nat Med. 2009 Aug;15(8):951-4. doi: 10.1038/nm.1974. Epub 2009 Jun 7.
8
Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm.
J Virol. 2009 Jul;83(14):7337-48. doi: 10.1128/JVI.00110-09. Epub 2009 May 13.
9
Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals.
Nature. 2009 Apr 2;458(7238):636-40. doi: 10.1038/nature07930. Epub 2009 Mar 15.
10
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial.
Lancet. 2008 Nov 29;372(9653):1881-1893. doi: 10.1016/S0140-6736(08)61591-3. Epub 2008 Nov 13.
Zotero 插件